RT Journal Article
SR Electronic
T1 Resistance to second-line injectables and treatment outcomes in multidrug-resistant and extensively drug-resistant tuberculosis cases
JF European Respiratory Journal
JO Eur Respir J
FD European Respiratory Society
SP 1155
OP 1159
DO 10.1183/09031936.00028708
VO 31
IS 6
A1 G. B. Migliori
A1 C. Lange
A1 R. Centis
A1 G. Sotgiu
A1 R. Mütterlein
A1 H. Hoffmann
A1 K. Kliiman
A1 G. De Iaco
A1 F. N. Lauria
A1 M. D. Richardson
A1 A. Spanevello
A1 D. M. Cirillo
A1 TBNET Study Group
YR 2008
UL http://erj.ersjournals.com/content/31/6/1155.abstract
AB No information is currently available on the influence of injectable second-line drugs on treatment outcomes of multidrug-resistant (MDR) and extensively drug-resistant (XDR) tuberculosis (TB) patients. To investigate this issue, a large series of MDR- and XDR-TB cases diagnosed in Estonia, Germany, Italy and the Russian Federation (Archangels Oblast) between 1999 and 2006 were analysed. All study sites performed drug susceptibility testing for first- and second-line anti-TB drugs, laboratory quality assurance and treatment delivery according to World Health Organization recommendations. Out of 4,583 culture-confirmed cases, 240 MDR- and 48 XDR-TB cases had a definitive outcome recorded (treatment success, death, failure). Among MDR- and XDR-TB cases, capreomycin resistance yielded a higher proportion of failure and death than capreomycin-susceptible cases. Resistance to capreomycin was independently associated with unfavourable outcome (logistic regression analysis: odds ratio 3.51). In the treatment of patients with multidrug-resistant and extensively drug-resistant tuberculosis, resistance to the injectable drug capreomycin was an independent predictor for therapy failure in this cohort. As Mycobacterium tuberculosis drug resistance is increasing worldwide, there is an urgent need for novel interventions in the fight against tuberculosis.